Taysha Gene Therapies (TSHA) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Climate Contaminant Environment Environmental Green Materials Nature Offset Package Packaging Pandemic Raw Materials Regeneration Regenerative Access African American Asian Benefits Black California Consumer Privacy Act Collective Bargaining Community Community Engagement Culture Customer Data Privacy Death Demographic Disability Diversity Diversity and Inclusion Drug Pricing Employee Engagement Ethnic Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Minority Perquisites Privacy Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skills Social Social Capital Society Stakeholder Supplier Supply Chain Talent Training Union Women Workforce Anti-corruption Assessment Assurance Attorneys General Audit Bonus Bribe Bribery Class Action Lawsuit Classified Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Independent Chair Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Purpose Quality Standard R&D Reputation Reputational Research and Development Responsibility Responsible Self-evaluation Special Meeting Strategy Sustainable Targets Tax Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On June 17, 2022, Taysha Gene Therapies, Inc. (the “Company”) held its 2022 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2022. Of the 40,473,945 shares outstanding as of the record date, 25,735,079 shares, or approximately 63.58%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.
Proposal No. 1: Election of two nominees to serve as directors until the 2025 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:


Name	Votes For	Votes Withheld
Phillip B. Donenberg	19,312,436	1,564,802
Sukumar Nagendran, M.D.	19,321,702	1,555,536

Broker Non-Votes: 4,857,841.
Both nominees were elected.
Proposal No. 2: Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2022. The votes were cast as follows:


	Votes For	Votes Against	Abstained
Ratification of appointment of Deloitte & Touche LLP	25,719,076	15,920	83